| Silvia Galvan Druke, CRNA | |
|
1501 N Campbell Ave Rm 5301, Tucson, AZ 85724-0001 | |
| (520) 626-7221 | |
| (520) 626-6943 |
| Full Name | Silvia Galvan Druke |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 12 Years |
| Location | 1501 N Campbell Ave Rm 5301, Tucson, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033457890 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | CRNA0909 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tucson Medical Center | Tucson, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ias Arizona Pllc | 7517312648 | 145 |
News Archive
Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China today announced that it has signed a cooperation agreement with Beijing Kanglian Medicines Co, Ltd, to develop, operate and implement for a new rural healthcare construction project in Hunan and Anhui provinces.
To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.
The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
A new stem cell-based approach to studying epilepsy has yielded a surprising discovery about what causes one form of the disease, and may help in the search for better medicines to treat all kinds of seizure disorders.
› Verified 7 days ago
| Entity Name | Banner -- University Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508809427 PECOS PAC ID: 7719899871 Enrollment ID: O20031105000694 |
News Archive
Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China today announced that it has signed a cooperation agreement with Beijing Kanglian Medicines Co, Ltd, to develop, operate and implement for a new rural healthcare construction project in Hunan and Anhui provinces.
To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.
The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
A new stem cell-based approach to studying epilepsy has yielded a surprising discovery about what causes one form of the disease, and may help in the search for better medicines to treat all kinds of seizure disorders.
› Verified 7 days ago
| Entity Name | B--umg Tucson Ap Physicians Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487178505 PECOS PAC ID: 1355616517 Enrollment ID: O20171013002780 |
News Archive
Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China today announced that it has signed a cooperation agreement with Beijing Kanglian Medicines Co, Ltd, to develop, operate and implement for a new rural healthcare construction project in Hunan and Anhui provinces.
To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.
The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
A new stem cell-based approach to studying epilepsy has yielded a surprising discovery about what causes one form of the disease, and may help in the search for better medicines to treat all kinds of seizure disorders.
› Verified 7 days ago
| Entity Name | Ias Arizona Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689359747 PECOS PAC ID: 7517312648 Enrollment ID: O20231010003129 |
News Archive
Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China today announced that it has signed a cooperation agreement with Beijing Kanglian Medicines Co, Ltd, to develop, operate and implement for a new rural healthcare construction project in Hunan and Anhui provinces.
To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.
The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
A new stem cell-based approach to studying epilepsy has yielded a surprising discovery about what causes one form of the disease, and may help in the search for better medicines to treat all kinds of seizure disorders.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Silvia Galvan Druke, CRNA 4221 Lanver Ln, Richmond, VA 23294-5628 Ph: (804) 346-0654 | Silvia Galvan Druke, CRNA 1501 N Campbell Ave Rm 5301, Tucson, AZ 85724-0001 Ph: (520) 626-7221 |
News Archive
Dehaier Medical Systems Ltd., an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China today announced that it has signed a cooperation agreement with Beijing Kanglian Medicines Co, Ltd, to develop, operate and implement for a new rural healthcare construction project in Hunan and Anhui provinces.
To evaluate efficacy of Calculus Bovis compound preparation (ICCBco) in the treatment of lung lesions in portal hypertensive rabbits with schistosomiasis as the experimental animal model, a research group in China performed a randomized, double-blind, controlled trial to observe pathological changes and pathological effect mechanism of expression of fibronectin and laminin in the lung tissue of portal hypertensive rabbits with schistosomiasis.
The Centre for Brain Research at the MedUni Vienna is regarded as a world leader in researching the mechanisms involved with multiple sclerosis (MS). Now, in a paper published in the highly respected journal Lancet Neurology, an international team of researchers from Edinburgh, Cleveland and Vienna, under the leadership of Hans Lassmann, Head of the Department of Neuroimmunology at the MedUni Vienna, has for the first time documented the pathological progress of the disease from its early to late stage and also shown that inflammatory and neurodegenerative processes have a role to play.
Regulus Therapeutics Inc. today announced the publication of new results in the journal Nature Biotechnology by Regulus scientists and collaborators. The new study demonstrated that systemic treatment of a microRNA therapeutic targeting microRNA-10b in tumor-bearing mice inhibits breast cancer metastasis. Cancer-related metastasis is a major cause of mortality and current cancer treatments have limited utility suppressing the metastatic spread of cancer cells. microRNA therapeutics targeting miR-10b represent a promising approach for the discovery and development of a novel anti-metastatic agent.
A new stem cell-based approach to studying epilepsy has yielded a surprising discovery about what causes one form of the disease, and may help in the search for better medicines to treat all kinds of seizure disorders.
› Verified 7 days ago
Steven Anderson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1625 N Campbell Ave, Tucson, AZ 85719 Phone: 520-827-8448 | |
Brigette Vyborny, DNP, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 N Campbell Ave, Tucson, AZ 85724 Phone: 420-694-0111 | |
Kimberly K Vinayak, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 3601 S 6th Ave, Tucson, AZ 85723 Phone: 520-792-1450 | |
Kitra Henker, RN Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1625 N Campbell Ave, Tucson, AZ 85719 Phone: 520-694-1100 | |
Melissa Schwarzenberger, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: Banner University Medical Center 1501 N Campbell Avenue, Tucson, AZ 85724 Phone: 520-694-0111 | |
Alysia Reina, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1501 N Campbell Ave, Tucson, AZ 85724 Phone: -- |